A Phase 1, Randomized, Double-Blind, Single-Dose Comparative Pharmacokinetic Study Comparing SB17 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Healthy Subjects

被引：0

作者：

Jeong, Hansol ^{[1
]}

Kang, Taeseung ^{[1
]}

Lee, Jiyoon ^{[1
]}

Im, Seongsik ^{[2
]}

机构：

[1] Samsung Bioepis Co Ltd, Product Evaluat Team, Incheon, South Korea

[2] Samsung Bioepis Co Ltd, Qual Evaluat Team, Incheon, South Korea

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

41531

引用

页码：AB9 / AB9

页数：1

共 50 条

[1] Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study
Jeong, Hansol
Kang, Taeseung
Lee, Jiyoon
Im, Seongsik
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2024, 62 (05) : 231 - 240
[2] A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis
Feldman, Steven R.
Narbutt, Joanna
Girolomoni, Giampiero
Brzezicki, Jan
Reznichenko, Nataliya
Zegadlo-Mylik, Maria Agnieszka
Pulka, Grazyna
Dmowska-Stecewicz, Magdalena
Klujszo, Elzbieta
Rekalov, Dmytro
Rajzer, Lidia
Lee, Jiyoon
Lee, Minkyung
Rho, Young Hee
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 440 - 447
[3] A Randomized, Double-Blind, Single-Dose Phase 1 Comparative Pharmacokinetic Study Comparing SB12 (Eculizumab Biosimilar) with Reference Eculizumab in Healthy Volunteers
Lee, Hyun A.
Jang, Hyerin
Kim, Yeonsoo
Jeong, Deokyoon
Lee, Jieun
Jung, Jin Ah
Demichelis, Roberta
[J]. BLOOD, 2021, 138
[4] A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects
Lee, Hyun A.
Kim, Sujung
Seo, Hyoryeong
Kim, Soyeon
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (10) : 959 - 966
[5] Pharmacokinetic Similarity of ABP 654, an Ustekinumab Biosimilar Candidate: Results from a Randomized, Double-blind Study in Healthy Subjects
Chow, Vincent
Mytych, Daniel T.
Das, Shyamal
Franklin, Janet
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (09): : 863 - 873
[6] New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double-Blind, Parallel-Group, Single-Dose Trial in Healthy Subjects
Balser, Sigrid
Nopora, Katrin
Koerner, Juliane
Wedemeyer, Ralph-Steven
Anschuetz, Maria
Schug, Barbara
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024,
[7] A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
Donghoon Shin
Yoon Jung Lee
Jihye Choi
Dahyoung Lee
Minjeong Park
Magdalena Petkova
[J]. Cancer Chemotherapy and Pharmacology, 2020, 86 : 567 - 575
[8] A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
Shin, Donghoon
Lee, Yoon Jung
Choi, Jihye
Lee, Dahyoung
Park, Minjeong
Petkova, Magdalena
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 567 - 575
[9] A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects
Farahani, Mohammad Farmahini
Maghzi, Parnian
Aryan, Nazanin Jafari
Payandemehr, Borna
Soni, Mayur
Azhdarzadeh, Morteza
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (12) : 1443 - 1450
[10] A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects
Lee, Hyun A.
Jang, Hyerin
Jeong, Deokyoon
Kim, Younsoo
Fuhr, Rainard
[J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (06) : 269 - 279

← 1 2 3 4 5 →